US Lucentis Competition Expectations Upended By Byooviz
Ranibizumab Biosimilar Competition Had Been Expected By End Of 2021 In US
Samsung Bioepis’ indication that it will not launch its FDA-approved ranibizumab biosimilar, Byooviz, before June 2022 has changed what we know about the competitive landscape for Lucentis in the US.
